178 related articles for article (PubMed ID: 19199865)
1. Role of tyrosine phosphatase inhibitors in cancer treatment with emphasis on SH2 domain-containing tyrosine phosphatases (SHPs).
Irandoust M; van den Berg TK; Kaspers GJ; Cloos J
Anticancer Agents Med Chem; 2009 Feb; 9(2):212-20. PubMed ID: 19199865
[TBL] [Abstract][Full Text] [Related]
2. Src homology region 2 (SH2) domain-containing phosphatase-1 dephosphorylates B cell linker protein/SH2 domain leukocyte protein of 65 kDa and selectively regulates c-Jun NH2-terminal kinase activation in B cells.
Mizuno K; Tagawa Y; Mitomo K; Arimura Y; Hatano N; Katagiri T; Ogimoto M; Yakura H
J Immunol; 2000 Aug; 165(3):1344-51. PubMed ID: 10903736
[TBL] [Abstract][Full Text] [Related]
3. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.
Neel BG; Gu H; Pao L
Trends Biochem Sci; 2003 Jun; 28(6):284-93. PubMed ID: 12826400
[TBL] [Abstract][Full Text] [Related]
4. Effects of Src homology domain 2 (SH2)-containing inositol phosphatase (SHIP), SH2-containing phosphotyrosine phosphatase (SHP)-1, and SHP-2 SH2 decoy proteins on Fc gamma RIIB1-effector interactions and inhibitory functions.
Nakamura K; Brauweiler A; Cambier JC
J Immunol; 2000 Jan; 164(2):631-8. PubMed ID: 10623804
[TBL] [Abstract][Full Text] [Related]
5. Targeting SHP-1, 2 and SHIP Pathways: A Novel Strategy for Cancer Treatment?
Dempke WCM; Uciechowski P; Fenchel K; Chevassut T
Oncology; 2018; 95(5):257-269. PubMed ID: 29925063
[TBL] [Abstract][Full Text] [Related]
6. A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail.
Poole AW; Jones ML
Cell Signal; 2005 Nov; 17(11):1323-32. PubMed ID: 16084691
[TBL] [Abstract][Full Text] [Related]
7. Impact of oncogenic protein tyrosine phosphatases in cancer.
Hardy S; Julien SG; Tremblay ML
Anticancer Agents Med Chem; 2012 Jan; 12(1):4-18. PubMed ID: 21707506
[TBL] [Abstract][Full Text] [Related]
8. SHP-1 in cell-cycle regulation.
López-Ruiz P; Rodriguez-Ubreva J; Cariaga AE; Cortes MA; Colás B
Anticancer Agents Med Chem; 2011 Jan; 11(1):89-98. PubMed ID: 21291405
[TBL] [Abstract][Full Text] [Related]
9. A mouse Fcgamma-Fcepsilon protein that inhibits mast cells through activation of FcgammaRIIB, SH2 domain-containing inositol phosphatase 1, and SH2 domain-containing protein tyrosine phosphatases.
Mertsching E; Bafetti L; Hess H; Perper S; Giza K; Allen LC; Negrou E; Hathaway K; Hopp J; Chung J; Perret D; Shields M; Saxon A; Kehry MR
J Allergy Clin Immunol; 2008 Feb; 121(2):441-447.e5. PubMed ID: 17949802
[TBL] [Abstract][Full Text] [Related]
10. Regulation of B cell signal transduction by SH2-containing protein-tyrosine phosphatases.
Siminovitch KA; Neel BG
Semin Immunol; 1998 Aug; 10(4):329-47. PubMed ID: 9695189
[TBL] [Abstract][Full Text] [Related]
11. Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2.
Barford D; Neel BG
Structure; 1998 Mar; 6(3):249-54. PubMed ID: 9551546
[TBL] [Abstract][Full Text] [Related]
12. B cell antigen receptor (BCR)-mediated formation of a SHP-2-pp120 complex and its inhibition by Fc gamma RIIB1-BCR coligation.
Nakamura K; Cambier JC
J Immunol; 1998 Jul; 161(2):684-91. PubMed ID: 9670943
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Targeting of Oncogenic Tyrosine Phosphatases.
Frankson R; Yu ZH; Bai Y; Li Q; Zhang RY; Zhang ZY
Cancer Res; 2017 Nov; 77(21):5701-5705. PubMed ID: 28855209
[TBL] [Abstract][Full Text] [Related]
14. Targeting PTPs with small molecule inhibitors in cancer treatment.
Jiang ZX; Zhang ZY
Cancer Metastasis Rev; 2008 Jun; 27(2):263-72. PubMed ID: 18259840
[TBL] [Abstract][Full Text] [Related]
15. Early signaling events triggered by peroxovanadium [bpV(phen)] are insulin receptor kinase (IRK)-dependent: specificity of inhibition of IRK-associated protein tyrosine phosphatase(s) by bpV(phen).
Band CJ; Posner BI; Dumas V; Contreres JO
Mol Endocrinol; 1997 Dec; 11(13):1899-910. PubMed ID: 9415395
[TBL] [Abstract][Full Text] [Related]
16. Specificity of the SH2 domains of SHP-1 in the interaction with the immunoreceptor tyrosine-based inhibitory motif-bearing receptor gp49B.
Wang LL; Blasioli J; Plas DR; Thomas ML; Yokoyama WM
J Immunol; 1999 Feb; 162(3):1318-23. PubMed ID: 9973385
[TBL] [Abstract][Full Text] [Related]
17. Cytoplasmic protein tyrosine phosphatases SHP-1 and SHP-2: regulators of B cell signal transduction.
Tamir I; Dal Porto JM; Cambier JC
Curr Opin Immunol; 2000 Jun; 12(3):307-15. PubMed ID: 10781410
[TBL] [Abstract][Full Text] [Related]
18. The phosphotyrosine phosphatase SHP-2 participates in a multimeric signaling complex and regulates T cell receptor (TCR) coupling to the Ras/mitogen-activated protein kinase (MAPK) pathway in Jurkat T cells.
Frearson JA; Alexander DR
J Exp Med; 1998 May; 187(9):1417-26. PubMed ID: 9565634
[TBL] [Abstract][Full Text] [Related]
19. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines.
Pathak MK; Yi T
J Immunol; 2001 Sep; 167(6):3391-7. PubMed ID: 11544330
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic cell phosphatase, SHP-1, is constitutively associated with the SH2 domain-containing leukocyte protein, SLP-76, in B cells.
Mizuno K; Katagiri T; Hasegawa K; Ogimoto M; Yakura H
J Exp Med; 1996 Aug; 184(2):457-63. PubMed ID: 8760799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
